No difference in survival after HLA mismatched versus HLA matched allogeneic stem cell transplantation in Ewing sarcoma patients with advanced disease

  1. Thiel, Uwe ORCID logo
  2. Schober, Sebastian Johannes ORCID logo
  3. Ranft, A.
  4. Gassmann, H.
  5. Jabar, S.
  6. Gall, K.
  7. von Lüttichau, I.
  8. Wawer, A.
  9. Koscielniak, E.
  10. Diaz, M. A.
  11. Ussowicz, Marek ORCID logo
  12. Kazantsev, Ilya ORCID logo
  13. Afanasyev, B.
  14. Merker, M.
  15. Klingebiel, Thomas ORCID logo
  16. Prete, A.
  17. Gruhn, Bernd ORCID logo
  18. Bader, P.
  19. Jürgens, H.
  20. , Uta ORCID logo
  21. Handgretinger, R.
  22. Burdach, S.
  23. Lang, P.

Download
s41409-020-01200-x.pdf 681,44KB
WeightNameValue
1000 Titel
  • No difference in survival after HLA mismatched versus HLA matched allogeneic stem cell transplantation in Ewing sarcoma patients with advanced disease
1000 Autor/in
  1. Thiel, Uwe |
  2. Schober, Sebastian Johannes |
  3. Ranft, A. |
  4. Gassmann, H. |
  5. Jabar, S. |
  6. Gall, K. |
  7. von Lüttichau, I. |
  8. Wawer, A. |
  9. Koscielniak, E. |
  10. Diaz, M. A. |
  11. Ussowicz, Marek |
  12. Kazantsev, Ilya |
  13. Afanasyev, B. |
  14. Merker, M. |
  15. Klingebiel, Thomas |
  16. Prete, A. |
  17. Gruhn, Bernd |
  18. Bader, P. |
  19. Jürgens, H. |
  20. , Uta |
  21. Handgretinger, R. |
  22. Burdach, S. |
  23. Lang, P. |
1000 Erscheinungsjahr 2021
1000 Publikationstyp
  1. Artikel |
1000 Online veröffentlicht
  • 2021-01-29
1000 Erschienen in
1000 Quellenangabe
  • 56(7):1550-1557
1000 Copyrightjahr
  • 2021
1000 Lizenz
1000 Verlagsversion
  • https://doi.org/10.1038/s41409-020-01200-x |
  • https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8263340/ |
1000 Publikationsstatus
1000 Sprache der Publikation
1000 Abstract/Summary
  • Patients with advanced Ewing sarcoma (AES) carry a poor prognosis. Retrospectively, we analyzed 66 AES patients treated with allogeneic stem cell transplantation (allo-SCT) receiving HLA-mismatched (group A, n = 39) versus HLA-matched grafts (group B, n = 27). Median age at diagnosis was 13 years, and 15 years (range 3-49 years) at allo-SCT. The two groups did not differ statistically in distribution of gender, age, remission status/number of relapses at allo-SCT, or risk stratum. 9/39 (23%) group A versus 2/27 (7%) group B patients developed severe acute graft versus host disease (GvHD). Of patients alive at day 100, 7/34 (21%) group A versus 9/19 (47%) group B patients had developed chronic GvHD. In group A, 33/39 (85%) versus 20/27 (74%) group B patients died of disease and 1/39 (3%) versus 1/27 (4%) patients died of complications, respectively. Altogether 12/66 (18%) patients survived in CR. Median EFS 24 months after allo-SCT was 20% in both groups, median OS was 27% (group A) versus 17% (group B), respectively. There was no difference in EFS and OS in AES patients transplanted with HLA-mismatched versus HLA-matched graft in univariate and multivariate analyses. In this analysis, CR at allo-SCT is a condition for survival (p < 0.02).
1000 Sacherschließung
lokal Transplantation Conditioning [MeSH]
lokal Adolescent [MeSH]
lokal Sarcoma, Ewing/therapy [MeSH]
lokal Bone metastases
lokal Adult [MeSH]
lokal Humans [MeSH]
lokal Hematopoietic Stem Cell Transplantation [MeSH]
lokal Retrospective Studies [MeSH]
lokal Middle Aged [MeSH]
lokal Article
lokal Graft vs Host Disease [MeSH]
lokal Young Adult [MeSH]
lokal Cancer immunotherapy
lokal Neoplasm Recurrence, Local [MeSH]
lokal Child [MeSH]
lokal Child, Preschool [MeSH]
1000 Liste der Beteiligten
  1. https://orcid.org/0000-0002-3574-7337|https://orcid.org/0000-0002-5650-4035|https://frl.publisso.de/adhoc/uri/UmFuZnQsIEEu|https://frl.publisso.de/adhoc/uri/R2Fzc21hbm4sIEgu|https://frl.publisso.de/adhoc/uri/SmFiYXIsIFMu|https://frl.publisso.de/adhoc/uri/R2FsbCwgSy4=|https://frl.publisso.de/adhoc/uri/dm9uIEzDvHR0aWNoYXUsIEku|https://frl.publisso.de/adhoc/uri/V2F3ZXIsIEEu|https://frl.publisso.de/adhoc/uri/S29zY2llbG5pYWssIEUu|https://frl.publisso.de/adhoc/uri/RGlheiwgTS4gQS4=|https://orcid.org/0000-0001-5725-4835|https://orcid.org/0000-0002-3818-6213|https://frl.publisso.de/adhoc/uri/QWZhbmFzeWV2LCBCLg==|https://frl.publisso.de/adhoc/uri/TWVya2VyLCBNLg==|https://orcid.org/0000-0001-5726-9092|https://frl.publisso.de/adhoc/uri/UHJldGUsIEEu|https://orcid.org/0000-0003-1862-0075|https://frl.publisso.de/adhoc/uri/QmFkZXIsIFAu|https://frl.publisso.de/adhoc/uri/SsO8cmdlbnMsIEgu|https://orcid.org/0000-0002-5435-7860|https://frl.publisso.de/adhoc/uri/SGFuZGdyZXRpbmdlciwgUi4=|https://frl.publisso.de/adhoc/uri/QnVyZGFjaCwgUy4=|https://frl.publisso.de/adhoc/uri/TGFuZywgUC4=
1000 Hinweis
  • DeepGreen-ID: eb9b0bdc932544f1afd705a47846d03e ; metadata provieded by: DeepGreen (https://www.oa-deepgreen.de/api/v1/), LIVIVO search scope life sciences (http://z3950.zbmed.de:6210/livivo), Crossref Unified Resource API (https://api.crossref.org/swagger-ui/index.html), to.science.api (https://frl.publisso.de/), ZDB JSON-API (beta) (https://zeitschriftendatenbank.de/api/), lobid - Dateninfrastruktur für Bibliotheken (https://lobid.org/resources/search)
1000 Label
1000 Dateien
1000 Objektart article
1000 Beschrieben durch
1000 @id frl:6442914.rdf
1000 Erstellt am 2023-04-26T16:16:01.737+0200
1000 Erstellt von 322
1000 beschreibt frl:6442914
1000 Zuletzt bearbeitet 2023-10-19T13:38:23.216+0200
1000 Objekt bearb. Thu Oct 19 13:38:23 CEST 2023
1000 Vgl. frl:6442914
1000 Oai Id
  1. oai:frl.publisso.de:frl:6442914 |
1000 Sichtbarkeit Metadaten public
1000 Sichtbarkeit Daten public
1000 Gegenstand von

View source